Norseth HML, Popat R, Schjesvold F(2026) Approach to Patients with Multiple Myeloma after BCMA targeted Therapy Curr Hematol Malig Rep, 21(1) DOI 10.1007/s11899-026-00793-2, PubMed 43033211
Merz M, Souto Filho JT, Voorhees PM, Einsele H, Schjesvold F, Cliff ERS, Mateos MV, Hungria V, Cohen YC, de Larrea CF, Beksac M, Landgren O, Usmani SZ, Costa LJ, Gagelmann N(2026) T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis J Hematol Oncol, 19(1) DOI 10.1186/s13045-026-01850-2, PubMed 42844619
Lonial S, Dimopoulos MA, Gavriatopoulou M, Kim K, Min CK, Oriol A, Moreira CCC, Quach H, Qiu L, Xia Z, Schjesvold F, Casas-Avilés I, Xu Y, Hungria V, Seval GC, Fang B, Kyriakou C, Prince HM, Zhuang J, Lin HC, Mateos MV, Špička I, Maiolino A, Vural F, Basu S, Dytfeld D, Fu C, Ho PJ, Joseph N, Low Met al.(2026) Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Lancet Oncol, 27(11), 1367-1381 DOI 10.1016/S1470-2045(26)00450-X, PubMed 42790445